Clinical and molecular characteristics of the 57 patients with AML
| Characteristics . | Value . |
|---|---|
| Sex, n (%) | |
| Male | 37 (65) |
| Female | 20 (35) |
| Age group, y, n (%) | |
| < 35 | 8 (14) |
| 35-60 | 22 (32) |
| > 60 | 25 (54) |
| Age, y | |
| Median | 57 |
| Range | 16-85 |
| Bone marrow blasts count, % | |
| Median | 87.1 |
| Range | 80-99 |
| Disease status, n (%) | |
| Diagnosis | 40 (70) |
| Relapse 1 | 8 (14) |
| Relapse > 2 or refractory | 9 (16) |
| French-American-British classification, n (%) | |
| M0 | 4 (7) |
| M1 | 12 (21) |
| M2 | 19 (39) |
| M3 | 4 (7) |
| M4 | 5 (9) |
| M5 | 7 (12) |
| M6 | 1 (4) |
| M7 | 0 (0) |
| Not determined | 5 (9) |
| Cytogenetic abnormalities, n (%) | |
| t(8;21) | 8 (14) |
| t(15;17) | 3 (5) |
| inv(16)/t(16;16) | 2 (4) |
| t(11q23) | 3 (5) |
| Complex karyotype (> 3 chromosomal abnormalities) | 3 (5) |
| Other abnormal karyotypes* | 2 (4) |
| Normal karyotype | 23 (40) |
| Not determined/no data | 13 (23) |
| Characteristics . | Value . |
|---|---|
| Sex, n (%) | |
| Male | 37 (65) |
| Female | 20 (35) |
| Age group, y, n (%) | |
| < 35 | 8 (14) |
| 35-60 | 22 (32) |
| > 60 | 25 (54) |
| Age, y | |
| Median | 57 |
| Range | 16-85 |
| Bone marrow blasts count, % | |
| Median | 87.1 |
| Range | 80-99 |
| Disease status, n (%) | |
| Diagnosis | 40 (70) |
| Relapse 1 | 8 (14) |
| Relapse > 2 or refractory | 9 (16) |
| French-American-British classification, n (%) | |
| M0 | 4 (7) |
| M1 | 12 (21) |
| M2 | 19 (39) |
| M3 | 4 (7) |
| M4 | 5 (9) |
| M5 | 7 (12) |
| M6 | 1 (4) |
| M7 | 0 (0) |
| Not determined | 5 (9) |
| Cytogenetic abnormalities, n (%) | |
| t(8;21) | 8 (14) |
| t(15;17) | 3 (5) |
| inv(16)/t(16;16) | 2 (4) |
| t(11q23) | 3 (5) |
| Complex karyotype (> 3 chromosomal abnormalities) | 3 (5) |
| Other abnormal karyotypes* | 2 (4) |
| Normal karyotype | 23 (40) |
| Not determined/no data | 13 (23) |
Patients with 3q26 abnormalities are not included in this study.